The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.
 
Giuseppe Lo Russo
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; italfarmaco; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); GlaxoSmithKline (Inst); MSD Oncology; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD; Roche
 
Monica Ganzinelli
No Relationships to Disclose
 
Francesco Sgambelluri
No Relationships to Disclose
 
Francesca Galli
No Relationships to Disclose
 
Arsela Prelaj
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Roche Italy
Travel, Accommodations, Expenses - Italfarmaco
 
Sara Manglaviti
No Relationships to Disclose
 
Achille Bottiglieri
No Relationships to Disclose
 
Rosa Maria Di Mauro
No Relationships to Disclose
 
Roberto Ferrara
Consulting or Advisory Role - BeiGene; Merck Sharp & Dohme
 
Andra Diana Dumitrascu
No Relationships to Disclose
 
Elisa Sottotetti
No Relationships to Disclose
 
Antonia Martinetti
No Relationships to Disclose
 
Alessandra Fabbri
No Relationships to Disclose
 
Eliana Rulli
No Relationships to Disclose
 
Filippo G. De Braud
Honoraria - Amgen Astellas BioPharma; BMS; Incyte; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Incyte; Menarini; Nerviano Medical Sciences; Nerviano Medical Sciences; Novartis Italy; Roche; Sanofi
Research Funding - Basilea Pharmaceutical; Bayer Health; Bristol-Myers Squibb/Medarex; Daiichi Sankyo Europe GmbH; Exelixis; Ignyta; incyte; Janssen Oncology; Kymab (Inst); Loxo (Inst); MedImmune; Merck KGaA; Merck Serono (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Valter Torri
No Relationships to Disclose
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Andrea Anichini
No Relationships to Disclose
 
Claudia Proto
Honoraria - AstraZeneca Canada; Bristol Myers Squibb Foundation; MSD; Roche
Consulting or Advisory Role - AstraZeneca Canada; MSD; Roche
Research Funding - AstraZeneca Canada; Bristol Myers Squibb Foundation; Celgene; Daiichi Sankyo; MSD; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca Canada; MSD; Roche
 
Roberta Mortarini
No Relationships to Disclose